Mirum Pharmaceuticals (MIRM) Gross Profit (2021 - 2026)

Mirum Pharmaceuticals' Gross Profit history runs 6 years deep, the most recent figure standing at $131.1 million for Q1 2026.

• In Q1 2026, Gross Profit rose 48.0% year-over-year to $131.1 million; the TTM figure through Mar 2026 stood at $463.6 million (up 58.53% YoY), while the FY2025 annual figure was $421.1 million, up 64.97% from the prior year.
• Gross Profit for Q1 2026 stood at $131.1 million, up from $120.7 million in the prior quarter.
• The five-year high for Gross Profit was $131.1 million in Q1 2026, with the low at $10.5 million in Q1 2022.
• The 5-year median for Gross Profit is $51.4 million (2024), against an average of $59.5 million.
• Peak annual rise in Gross Profit reached 1795.71% in 2022, while the deepest fall reached 36.0% in 2022.
• Mirum Pharmaceuticals' Gross Profit stood at $23.4 million in 2022, then jumped by 90.22% to $44.5 million in 2023, then soared by 72.08% to $76.6 million in 2024, then jumped by 57.46% to $120.7 million in 2025, then increased by 8.63% to $131.1 million in 2026.
• Business Quant data shows MIRM's Gross Profit at $131.1 million in Q1 2026, $120.7 million in Q4 2025, and $107.5 million in Q3 2025.